Astellas to shutter NY facilities, cut jobs

Astellas Pharma is the latest drugmaker to plan a shutdown of U.S. facilities. The Japanese company will shutter operations in Ardsley and Melville, NY, both of which it acquired in the $4 billion buyout of OSI Pharmaceuticals, Dow Jones reports. Roughly 150 workers are employed at the sites, which will close by June 2011.

Astellas snapped up OSI (NASDAQ: OSIP) in a hostile bid, aiming to gain the latter's blockbuster cancer drug Tarceva. OSI also had operations in Farmingdale, N.Y., and Cedar Knolls, N.J., and those facilities will remain open--at least for now. An Astellas spokeswoman tells the news service that long-term decisions about these two will be made when it's finished with integration planning.

Mergers have claimed a variety of pharma facilities in the U.S.--and abroad--as companies such as Pfizer (which bought Wyeth) and Merck (which bought Schering-Plough) try to wring costs out of their combined operations. 

- read the Dow Jones news
- get more from In the Pipeline

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.